| Name | Title | Contact Details |
|---|
AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients` lives with clear unmet medical needs. AVEO`s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics.
Galileo Laboratories is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Word & Brown Companies, headquartered in Orange, Calif., provides services through more than 50,000 brokers to nearly 60,000 employers with more than 6 million eligible employees. During its more than 20-year-span, The Word & Brown Companies has become the nation’s recognized leader in developing and offering innovative technology, health benefit plan models, and sophisticated employee benefits services to companies of all sizes. The Word & Brown Companies includes: Word & Brown General Agency, the leader in developing and distributing health benefit plan models and solutions to licensed brokers in California and Nevada; CHOICE Administrators, the nation’s leader in developing and administrating employee-choice health benefit programs; CONEXIS, providing benefits solutions to clients nationwide, with expertise in COBRA and HIPAA administrative services, Direct Bill Services, and Flexible Benefits Administration, including Flexible Spending Accounts (FSA) and Section 132 Commuter Benefits; Quotit Corporation the leading Internet application service provider for the health insurance/employee benefits industry; and HealthCompare, which works with brokers and carriers to help individuals and families easily research, compare, buy, and enroll in the right health insurance plan at the right price.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
Biolyse Pharma Corporation is a St Catharines, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.